MX2014007262A - Full length antibody display system for eukaryotic cells and its use. - Google Patents

Full length antibody display system for eukaryotic cells and its use.

Info

Publication number
MX2014007262A
MX2014007262A MX2014007262A MX2014007262A MX2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A
Authority
MX
Mexico
Prior art keywords
population
full length
eukaryotic cells
length antibody
membrane
Prior art date
Application number
MX2014007262A
Other languages
Spanish (es)
Inventor
Hendrik Knoetgen
Peter Michael Huelsmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014007262A publication Critical patent/MX2014007262A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Herein is reported a method of selecting a cell expressing a bispecific antibody comprising the steps of (a) generating a population of eukaryotic cells by transduction with a population of lentiviral virus particles, whereby each cell of the population of cells displays a membrane-bound full length antibody which is encoded by the lentiviral nucleic acid, and which specifically binds to two or more antigens or two or more epitopes on the same antigen, and (b) selecting from the population of eukaryotic cells a cell depending on the properties of the displayed membrane-bound full length antibody, whereby each lentiviral virus particle of the population of lentiviral virus particles comprises a bicistronic expression cassette comprising the EV71-IRES for the expression of the membrane-bound antibody.
MX2014007262A 2011-12-22 2012-12-19 Full length antibody display system for eukaryotic cells and its use. MX2014007262A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195375 2011-12-22
EP12179029 2012-08-02
PCT/EP2012/076163 WO2013092720A1 (en) 2011-12-22 2012-12-19 Full length antibody display system for eukaryotic cells and its use

Publications (1)

Publication Number Publication Date
MX2014007262A true MX2014007262A (en) 2014-08-01

Family

ID=47458959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007262A MX2014007262A (en) 2011-12-22 2012-12-19 Full length antibody display system for eukaryotic cells and its use.

Country Status (12)

Country Link
US (1) US20150038354A1 (en)
EP (1) EP2794662A1 (en)
JP (1) JP2015503907A (en)
KR (1) KR20140107295A (en)
CN (1) CN104011080B (en)
BR (1) BR112014013035A2 (en)
CA (1) CA2854246A1 (en)
HK (1) HK1200849A1 (en)
MX (1) MX2014007262A (en)
RU (1) RU2625033C2 (en)
SG (1) SG11201403445YA (en)
WO (1) WO2013092720A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EA034306B1 (en) * 2014-10-20 2020-01-27 Зе Скриппс Рисёрч Инститьют Proximity based methods for selection of binding partners
CN104818295A (en) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 Method for preparing and screening cell line expressing bispecific antibody
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
IL260743B2 (en) * 2016-02-04 2024-03-01 Trianni Inc Enhanced production of immunoglobulins
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
JP7108551B2 (en) * 2016-03-19 2022-07-28 エクスマ バイオテック コーポレイション Methods and compositions for transducing lymphocytes and their controlled increase
WO2018060239A1 (en) 2016-09-29 2018-04-05 F. Hoffmann-La Roche Ag Improved method for selecting polypeptide producing cells
GB201720351D0 (en) 2017-12-06 2018-01-17 Iontas Ltd Selecting for developability in drug discovery
CN110872356B (en) * 2018-09-03 2023-06-13 广西慧宝源健康产业有限公司 Bispecific antibodies and methods of use thereof
WO2020177719A1 (en) * 2019-03-05 2020-09-10 信达生物制药(苏州)有限公司 Yeast display system for displaying and secreting polypeptide of interest and use thereof
WO2021057726A1 (en) * 2019-09-23 2021-04-01 南开大学 SCREENING OF FC SPECIFICALLY BINDING TO FCγR BY USING MAMMALIAN DISPLAY
CN113150122B (en) * 2021-05-19 2023-03-17 上海儒克生物科技有限公司 Preparation method of high-throughput whole rabbit source monoclonal antibody
WO2023118670A1 (en) * 2021-12-23 2023-06-29 Helsingin Yliopisto Method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
JP4213224B2 (en) * 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド Method for producing multispecific antibody having heteromultimer and common component
JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
WO2001029246A1 (en) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1306272C (en) 2000-11-17 2007-03-21 罗切斯特大学 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2462857C (en) 2001-10-05 2012-01-24 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213761A (en) 2001-10-25 2005-04-12 Genentech Inc Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition
BR0213950A (en) 2001-11-07 2004-08-24 Cytos Biotechnology Ag Antigen Arrangements for the Treatment of Allergic Eosinofolic Diseases
PL369685A1 (en) 2001-11-07 2005-05-02 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
MXPA04004634A (en) * 2001-11-16 2004-08-12 Idec Pharma Corp Polycistronic expression of antibodies.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN1429916A (en) * 2001-12-30 2003-07-16 韩泽广 Scaled procaryotic cell and eucaryotic cell internal antibody and antigen library construction and screening
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
CN1665565A (en) 2002-07-19 2005-09-07 赛托斯生物技术公司 GHRELIN-carrier conjugates
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
MXPA05010007A (en) * 2003-03-20 2006-03-10 Alphavax Inc Improved alphavirus replicons and helper constructs.
KR20050115913A (en) 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Melan-a peptide analogue-virus-like-particle conjugates
US20060286035A1 (en) 2003-04-29 2006-12-21 Cytos Biotechnology Ag Methods and compositions for modulating the interaction between adiponectin and its receptor
WO2004102198A2 (en) 2003-05-15 2004-11-25 Cytos Biotechnology Ag Selection of b cells with specificity of interest: method of preparation and use
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
CN1289668C (en) * 2003-06-12 2006-12-13 北京安波特基因工程技术有限公司 In vitro molecular directed evolution method for reshaping antibody
RU2375076C2 (en) 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Completed virus-like particles
CN1852925A (en) 2003-07-15 2006-10-25 人类多克隆治疗公司 Humanized immunoglobulin loci
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
RS54450B1 (en) 2003-11-05 2016-06-30 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
KR20060128924A (en) 2004-01-20 2006-12-14 사이토스 바이오테크놀로지 아게 Ghrelin-carrier conjugates
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005108425A1 (en) 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AU2005249218A1 (en) 2004-06-02 2005-12-15 Cytos Biotechnology Ag Medical uses of carrier conjugates of non-human TNF-peptides
WO2005117983A2 (en) 2004-06-02 2005-12-15 Cytos Biotechnology Ag Carrier conjugates of tnf-peptides
EP1784210A2 (en) 2004-08-04 2007-05-16 Cytos Biotechnology AG Carrier conjugates of gnrh-peptides
EP1791870A1 (en) 2004-09-21 2007-06-06 Cytos Biotechnology AG Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
CA2580919A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
AU2005315658A1 (en) 2004-12-13 2006-06-22 Cytos Biotechnology Ag IL-15 antigen arrays and uses thereof
WO2006097530A2 (en) 2005-03-18 2006-09-21 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP1975239A1 (en) * 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2098536A1 (en) * 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN103261220B (en) * 2010-08-16 2016-06-15 诺夫免疫股份有限公司 For generating the method for polyspecific and multivalent antibody
CA2791109C (en) * 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules

Also Published As

Publication number Publication date
EP2794662A1 (en) 2014-10-29
BR112014013035A2 (en) 2018-10-09
KR20140107295A (en) 2014-09-04
WO2013092720A1 (en) 2013-06-27
RU2625033C2 (en) 2017-07-11
US20150038354A1 (en) 2015-02-05
SG11201403445YA (en) 2014-07-30
CA2854246A1 (en) 2013-06-27
CN104011080A (en) 2014-08-27
HK1200849A1 (en) 2015-08-14
JP2015503907A (en) 2015-02-05
CN104011080B (en) 2017-10-20
RU2014129736A (en) 2016-02-20

Similar Documents

Publication Publication Date Title
MX2014007262A (en) Full length antibody display system for eukaryotic cells and its use.
AU2018397910A1 (en) Nucleic acid-containing lipid nano-particle and use thereof
MX2018004157A (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor.
PH12017500596A1 (en) Car expression vector and car-expressing t cells
AR091116A1 (en) BISPECIFIC ANTIBODIES AND THEIR METHODS OF USE
MX2019010583A (en) Antibodies against pd-l1.
GB201108236D0 (en) Method
WO2012092376A3 (en) Comprehensive monoclonal antibody generation
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2014011993A3 (en) Epitope spreading associated with car t-cells
MY164647A (en) Cea antibodies
PH12014501758B1 (en) Cd47 antibodies and methods of use thereof
CR20130669A (en) BISPECETIC MOLECULES OF UNIÒN TO ANTIGEN T-CELL ACTIVATORS
NZ611600A (en) Means and methods for producing high affinity antibodies
AU2012307816A8 (en) Anti-alphabeta TCR antibody
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
UA111340C2 (en) ANTIBODY THAT SPECIFICALLY Binds to TNF-ALFA OF HUMAN
MX2015011781A (en) Cell culture media and methods of antibody production.
BR112014014239A2 (en) method, method for producing an antibody, expression vector, method for selecting a recombinant mammalian cell, use of an expression vector, expression plasmid, one aspect, method for selecting an eukaryotic cell expressing an antibody, expression plasmid expression, use of an expression plasmid and expression plasmid or use or method
NZ628251A (en) Cd8+t-cell subsets as markers for prediction of delayed fracture healing
WO2012178150A3 (en) Methods for developing antigen-specific antibody-producing cell lines and monoclonal antibodies
GB201207155D0 (en) Antibodies
WO2013009767A3 (en) Facs-based method for obtaining an antibody sequence
SG10201806428YA (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes